Decision Making in Big Pharma vs. Small Pharma

On many occasions, I have the opportunity to speak with leaders at small pharmaceutical and biotech companies. They always say, “We don’t operate like big pharma” or “I’m not interested in hearing the best practices from big pharma.” As a younger and less experienced leader from big pharma, I couldn’t fathom what they meant by[…]

Clinical Operations Process Improvement Metrics (Part V – Take the Long View)

In previous blog posts, I’ve zeroed in on two of the three main areas where companies struggle with metrics. This time, I’ll focus on the third – the use of short-sighted metrics. “Localized metrics” are metrics that measure small (individual or departmental) goals. They do not have a link to broader company objectives. This use can[…]

portfolio assessment

Laying the Foundation for Pharma Pipeline Decisions

It is well known that the days of Pharma thriving on blockbuster drugs are long gone. The drug development process is lengthy – currently spanning 15 years. And drugs on the market are coming off patent with few drugs to replace the significant revenue loss. As a result, measures to cut costs or just control[…]